Physician profile
Mark A Manning
NPI 1922243617
$587.22
in general payments reported to CMS, 2019-2025
15 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $47.94 · 2021: $101 · 2022: $15.67 · 2023: $45.11 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $311.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $133.67 | 2020-2025 | Dermabond Prineo, Echelon Flex, Surgiflo Hemostatic Matrix |
| Teva Pharmaceuticals USA, INC. | $66.94 | 2025 | Austedo Xr |
| Abbvie INC. | $62.19 | 2019-2021 | |
| Eisai INC. | $46.46 | 2021 | |
| Pfizer INC. | $44.59 | 2019 | |
| Amgen INC. | $42.20 | 2019-2020 | |
| Astellas Pharma US INC | $32.87 | 2025 | Veozah |
| Hologic Sales and Service, LLC | $30.86 | 2020-2023 | Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $21.39 | 2025 | |
| Sage Therapeutics, LLC | $21.29 | 2025 | Zurzuvae |
| Shield Therapeutics INC | $20.68 | 2025 | |
| Minerva Surgical, INC | $19.18 | 2025 | |
| Organon LLC | $16.43 | 2025 | Nexplanon |
| Coopersurgical, INC. | $15.40 | 2025 | Sos |
| Mylan Pharmaceuticals INC. | $13.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Manning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.